Abstract
Arsenite exposure is associated with an increased risk of human lung cancer. However, the molecular mechanisms underlying the arsenite-induced human lung carcinogenesis remain elusive. In this study, we demonstrated that arsenite upregulates cyclin D1 expression/activity to promote the growth of human bronchial epithelial Beas-2B cells. In this process, the JNKs (c-Jun N-terminal kinases)/c-Jun cascade is elicited. The inhibition of JNKs or c-Jun by chemical or genetic inhibitors blocks the cyclin D1 induction mediated by arsenite. Furthermore, using a loss of function mutant of p85 (Δp85, a subunit of PI3K) or dominant-negative Akt (DN-Akt), we showed that PI3K and Akt act as the upstream regulators of JNKs and c-Jun in arsenite-mediated growth promotion. Overall, our data suggest a pathway of PI- 3K/Akt/JNK/c-Jun/cylin D1 signaling in response to arsenite in human bronchial epithelial cells.
Keywords: PI-3K, Akt, JNK, c-Jun, cyclin D1, arsenite, cell proliferation
Current Cancer Drug Targets
Title: PI3K/Akt/JNK/c-Jun Signaling Pathway is a Mediator for Arsenite- Induced Cyclin D1 Expression and Cell Growth in Human Bronchial Epithelial Cells
Volume: 9 Issue: 4
Author(s): Jin Ding, Beifang Ning, Yi Huang, Dongyun Zhang, Jingxia Li, Chang-Yan Chen and Chuanshu Huang
Affiliation:
Keywords: PI-3K, Akt, JNK, c-Jun, cyclin D1, arsenite, cell proliferation
Abstract: Arsenite exposure is associated with an increased risk of human lung cancer. However, the molecular mechanisms underlying the arsenite-induced human lung carcinogenesis remain elusive. In this study, we demonstrated that arsenite upregulates cyclin D1 expression/activity to promote the growth of human bronchial epithelial Beas-2B cells. In this process, the JNKs (c-Jun N-terminal kinases)/c-Jun cascade is elicited. The inhibition of JNKs or c-Jun by chemical or genetic inhibitors blocks the cyclin D1 induction mediated by arsenite. Furthermore, using a loss of function mutant of p85 (Δp85, a subunit of PI3K) or dominant-negative Akt (DN-Akt), we showed that PI3K and Akt act as the upstream regulators of JNKs and c-Jun in arsenite-mediated growth promotion. Overall, our data suggest a pathway of PI- 3K/Akt/JNK/c-Jun/cylin D1 signaling in response to arsenite in human bronchial epithelial cells.
Export Options
About this article
Cite this article as:
Ding Jin, Ning Beifang, Huang Yi, Zhang Dongyun, Li Jingxia, Chen Chang-Yan and Huang Chuanshu, PI3K/Akt/JNK/c-Jun Signaling Pathway is a Mediator for Arsenite- Induced Cyclin D1 Expression and Cell Growth in Human Bronchial Epithelial Cells, Current Cancer Drug Targets 2009; 9 (4) . https://dx.doi.org/10.2174/156800909788486740
DOI https://dx.doi.org/10.2174/156800909788486740 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Dedication to Professor Tony Dodi
Current Cancer Therapy Reviews Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets Anti-Proliferative, Anti-Inflammatory, Anti-Ulcerogenic and Wound Healing Properties of Chitosan
Current Bioactive Compounds Regulatory Role of G Protein-coupled Receptors in Pancreatic Cancer Development and Progression
Current Medicinal Chemistry PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far?
Current Medicinal Chemistry MicroRNAs in Tumorigenesis
Current Pharmaceutical Biotechnology Bromodomain-Containing Protein 4: A Druggable Target
Current Drug Targets Hypomethylation and Activation of Syncytin-1 Gene in Endometriotic Tissue
Current Pharmaceutical Design Comparison of Methods for Sequential Screening of Large Compound Sets
Combinatorial Chemistry & High Throughput Screening A Structure-Function Perspective of Jak2 Mutations and Implications for Alternate Drug Design Strategies: The Road not Taken
Current Medicinal Chemistry Oxytocin as a Potential Adjuvant Against COVID-19 Infection
Endocrine, Metabolic & Immune Disorders - Drug Targets Contrast Agents in X-Ray Computed Tomography and Its Applications in Oncology
Anti-Cancer Agents in Medicinal Chemistry Combining Anti-Epidermal Growth Factor Receptor (EGFR) and Anti-Angiogenic Strategies in Advanced NSCLC: We Should have Known Better...
Current Pharmaceutical Design Analysis of Key GO Terms and KEGG Pathways Associated with Carcinogenic Chemicals
Combinatorial Chemistry & High Throughput Screening Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry Biotransformation of Bioactive Natural Products for Pharmaceutical Lead Compounds
Current Organic Chemistry Cucurbitacin B Induces DNA Damage, G2/M Phase Arrest, and Apoptosis Mediated by Reactive Oxygen Species (ROS) in Leukemia K562 Cells
Anti-Cancer Agents in Medicinal Chemistry miR-126 as a Therapeutic Agent for Diabetes Mellitus
Current Pharmaceutical Design Targeting the Type I Insulin-Like Growth Factor System for Breast Cancer Therapy
Current Drug Targets